Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The role of blinatumomab followed by HSCT in paediatric patients with ALL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.01.20
Views: 643
Rating:

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

Prof Franco Locatelli speaks to ecancer at the 2020 ALL Assembly meeting in Frankfurt about the latest data surrounding the use of blinatumomab followed transplantation in paediatric acute lymphoblastic leukaemia (ALL) patients.

In one study, he states that two cycles of blinatumomab successfully translated into a better MRD clearance, disease-free and overall survival - allowing patients to receive an allograft.

Prof Locatelli also mentions some unpublished data, which clearly shows that a TBI containing regimen is able to offer a better probability of leukaemia-free survival in patients with B-cell precursor ALL receiving an allograft.

 

Related videos

follow us

WIN 2020


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation